- Home
- OPP vs MDXH Comparison
OPP vs MDXH Comparison
Compare OPP & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPP
- MDXH
- Stock Information
- Founded
- OPP 2010
- MDXH 2003
- Country
- OPP United States
- MDXH Belgium
- Employees
- OPP N/A
- MDXH N/A
- Industry
- OPP Finance/Investors Services
- MDXH
- Sector
- OPP Finance
- MDXH
- Exchange
- OPP Nasdaq
- MDXH Nasdaq
- Market Cap
- OPP 204.0M
- MDXH 203.4M
- IPO Year
- OPP N/A
- MDXH 2021
- Fundamental
- Price
- OPP $8.11
- MDXH $4.45
- Analyst Decision
- OPP
- MDXH Buy
- Analyst Count
- OPP 0
- MDXH 1
- Target Price
- OPP N/A
- MDXH $6.00
- AVG Volume (30 Days)
- OPP 108.0K
- MDXH 258.4K
- Earning Date
- OPP 01-01-0001
- MDXH 11-12-2025
- Dividend Yield
- OPP 14.41%
- MDXH N/A
- EPS Growth
- OPP N/A
- MDXH N/A
- EPS
- OPP N/A
- MDXH N/A
- Revenue
- OPP N/A
- MDXH $98,953,000.00
- Revenue This Year
- OPP N/A
- MDXH $24.78
- Revenue Next Year
- OPP N/A
- MDXH $21.20
- P/E Ratio
- OPP N/A
- MDXH N/A
- Revenue Growth
- OPP N/A
- MDXH 22.56
- 52 Week Low
- OPP $7.26
- MDXH $1.35
- 52 Week High
- OPP $8.83
- MDXH $5.33
- Technical
- Relative Strength Index (RSI)
- OPP 39.85
- MDXH 49.39
- Support Level
- OPP $8.05
- MDXH $4.28
- Resistance Level
- OPP $8.15
- MDXH $4.98
- Average True Range (ATR)
- OPP 0.09
- MDXH 0.29
- MACD
- OPP 0.01
- MDXH -0.05
- Stochastic Oscillator
- OPP 42.62
- MDXH 33.84
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.